Published in PLoS One on March 19, 2010
Akt-mediated foxo1 inhibition is required for liver regeneration. Hepatology (2015) 1.46
ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer. Cancer Cell (2017) 1.38
PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol (2012) 1.35
Posttranslational regulation of Akt in human cancer. Cell Biosci (2014) 1.27
Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate (2010) 1.19
Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. J Cell Physiol (2010) 1.13
Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. J Biol Chem (2012) 1.02
Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol (2010) 1.01
Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Am J Pathol (2012) 1.00
ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers. Oncogene (2014) 0.98
H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes. Nat Struct Mol Biol (2012) 0.98
Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer. Pharmacol Rev (2014) 0.96
Phospholipase D2 mediates survival signaling through direct regulation of Akt in glioblastoma cells. J Biol Chem (2013) 0.95
Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. Prostate Cancer (2013) 0.94
ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1. J Biol Chem (2014) 0.93
PI3K and AKT: Unfaithful Partners in Cancer. Int J Mol Sci (2015) 0.92
The PI3K/AKT Pathway and Renal Cell Carcinoma. J Genet Genomics (2015) 0.90
SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation. Oncogene (2012) 0.89
Modulation of the Akt pathway reveals a novel link with PERK/eIF2α, which is relevant during hypoxia. PLoS One (2013) 0.88
Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects. Proteins (2014) 0.88
ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation. Cancer Lett (2013) 0.87
Cross talk of tyrosine kinases with the DNA damage signaling pathways. Nucleic Acids Res (2015) 0.86
Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene (2013) 0.85
Modification of Akt by SUMO conjugation regulates alternative splicing and cell cycle. Cell Cycle (2013) 0.82
Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer. Mol Cancer (2014) 0.82
Development of novel ACK1/TNK2 inhibitors using a fragment-based approach. J Med Chem (2015) 0.82
Drosophila activated Cdc42 kinase has an anti-apoptotic function. PLoS Genet (2012) 0.81
Multiple host kinases contribute to Akt activation during Salmonella infection. PLoS One (2013) 0.79
Development of a human breast-cancer derived cell line stably expressing a bioluminescence resonance energy transfer (BRET)-based phosphatidyl inositol-3 phosphate (PIP3) biosensor. PLoS One (2014) 0.79
Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget (2015) 0.78
Determinants of the tumor suppressor INPP4B protein and lipid phosphatase activities. Biochem Biophys Res Commun (2013) 0.78
Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Res (2015) 0.78
Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung. Transl Lung Cancer Res (2013) 0.77
Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Oncotarget (2015) 0.77
Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway. Cancer Biol Ther (2015) 0.77
Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis. Oncotarget (2016) 0.76
The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer. Oncotarget (2016) 0.75
SP600125 induces Src and type I IGF receptor phosphorylation independent of JNK. Int J Mol Sci (2014) 0.75
Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures. Oncotarget (2016) 0.75
Involvement of Activated Cdc42 Kinase1 in Colitis and Colorectal Neoplasms. Med Sci Monit (2016) 0.75
Non-canonical Activation of Akt in Serum-Stimulated Fibroblasts, Revealed by Comparative Modeling of Pathway Dynamics. PLoS Comput Biol (2015) 0.75
AKT goes cycling. Cancer Control (2014) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J (1996) 16.68
The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell (1995) 11.86
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature (1995) 11.61
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science (1997) 8.17
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene (2005) 7.50
Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science (1998) 6.79
Dynamic FoxO transcription factors. J Cell Sci (2007) 6.30
Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res (2005) 4.74
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat Cell Biol (2007) 3.68
The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene (2005) 3.42
AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol (2001) 2.81
PTEN, more than the AKT pathway. Carcinogenesis (2007) 2.70
A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature (1993) 2.60
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A (2007) 2.34
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res (2004) 2.28
The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A (2006) 2.23
Binding of the PX domain of p47(phox) to phosphatidylinositol 3,4-bisphosphate and phosphatidic acid is masked by an intramolecular interaction. EMBO J (2002) 2.09
Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer (2003) 2.03
Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem (2001) 1.98
Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res (2005) 1.97
Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci U S A (2005) 1.82
PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am J Physiol Endocrinol Metab (2005) 1.68
The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol (2006) 1.57
Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. Mol Biol Cell (2006) 1.37
Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proc Natl Acad Sci U S A (2006) 1.37
An SH2 domain-dependent, phosphotyrosine-independent interaction between Vav1 and the Mer receptor tyrosine kinase: a mechanism for localizing guanine nucleotide-exchange factor action. J Biol Chem (2003) 1.32
Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn J Cancer Res (1997) 1.28
The Akt isoforms are present at distinct subcellular locations. Am J Physiol Cell Physiol (2009) 1.23
The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol (2004) 1.21
Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase. J Biol Chem (2002) 1.20
Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate (2010) 1.19
Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck. J Biol Chem (2003) 1.13
PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol (2007) 1.08
Activated AKT/PKB signaling in C. elegans uncouples temporally distinct outputs of DAF-2/insulin-like signaling. BMC Dev Biol (2006) 1.01
Differential mechanisms of constitutive Akt/PKB activation and its influence on gene expression in pancreatic cancer cells. Jpn J Cancer Res (2002) 0.90
Stimulation of Ras guanine nucleotide exchange activity of Ras-GRF1/CDC25(Mm) upon tyrosine phosphorylation by the Cdc42-regulated kinase ACK1. J Biol Chem (2000) 0.81
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol (2007) 8.29
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas (2010) 5.01
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol (2008) 4.45
Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum. Bioinformatics (2005) 4.26
HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell (2007) 3.99
Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med (2011) 3.83
Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med (2002) 3.83
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res (2008) 3.63
Retracted MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem (2008) 3.63
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Retracted Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem (2002) 2.97
Retracted Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem (2003) 2.89
Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol (2005) 2.88
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst (2002) 2.77
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer (2010) 2.74
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53
Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril (2002) 2.48
Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med (2015) 2.46
Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J Immunol (2007) 2.45
Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res (2003) 2.43
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas (2010) 2.43
Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer (2009) 2.38
microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood (2010) 2.37
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A (2007) 2.34
Retracted MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem (2010) 2.34
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res (2012) 2.31
MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem (2006) 2.20
Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst (2008) 2.20
Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol (2004) 2.14
Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem (2004) 2.11
Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol (2008) 2.11
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest (2008) 2.11
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol (2009) 2.10
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A (2005) 2.00
Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem (2008) 1.98
Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol (2006) 1.98
Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res (2005) 1.97
Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol Aging (2004) 1.97
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A (2006) 1.96
Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst (2011) 1.92
NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas (2010) 1.90
Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol (2012) 1.83
Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem (2002) 1.82
Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? J Natl Cancer Inst (2013) 1.81
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer (2014) 1.77
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets (2010) 1.76
SHIP deficiency causes Crohn's disease-like ileitis. Gut (2010) 1.76
Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther (2005) 1.75
An RCS-like retinal dystrophy phenotype in mer knockout mice. Invest Ophthalmol Vis Sci (2003) 1.75
AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci (2005) 1.72
Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol (2003) 1.72
Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood (2006) 1.71
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene (2005) 1.70
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol (2006) 1.69
Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A (2008) 1.66
Immunohistochemical staining for c-Kit (CD117) is a rare event in human colorectal carcinoma. Clin Colorectal Cancer (2002) 1.64
LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res (2011) 1.64
Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer (2006) 1.64
Retracted Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem (2003) 1.63
EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer (2012) 1.63
p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res (2003) 1.62
Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res (2006) 1.61
Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol (2005) 1.61
Standard preanalytical coding for biospecimens: defining the sample PREanalytical code. Cancer Epidemiol Biomarkers Prev (2010) 1.60
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest (2005) 1.55
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2011) 1.52
Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol (2011) 1.51
Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med (2013) 1.51
Sun protection at elementary schools: a cluster randomized trial. J Natl Cancer Inst (2010) 1.50
Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res (2005) 1.49
Retracted AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem (2003) 1.49
Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew Chem Int Ed Engl (2005) 1.49